iqvia glp-1 prescriptions q3 2024 semaglutide tirzepatide Are Up, Health Services Utilization Down, and GLP-1s Are a Major Growth Driver: IQVIA's Update India's obesity and diabetes market

Many patients do not see consistent weight reduction until they move up to 5mg or beyond, depending on how their body responds

Future research: Its crucial to acknowledge that the majority of these studies have been performed in vitro or on animal subjects

Key results: Average weight loss: 14.9 percent (approximately 33 pounds for a 220-pound individual) 50 percent of participants lost at least 15 percent of body weight 32 percent of participants lost at least 20 percent Significant improvements in waist circumference, blood pressure, HbA1c, and quality of life Brand Names and Availability Semaglutide is marketed as Ozempic for type 2 diabetes and Wegovy for weight loss

This has been the best experience